After decades of excruciating pain, a breakthrough sickle cell disease treatment made all the difference for one patient.

In July 2025, Novartis Pharmaceuticals announced a phase III study to assess efficacy and safety of crizanlizumab (5 mg/kg) ...

CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.

A groundbreaking new medical dataset is poised to revolutionize health care in Africa by improving chatbots' understanding of ...

An expert discusses how integrating newer NMIBC therapies faces operational barriers including administration logistics, staff training and formulary restrictions, while solutions require better ...